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Purpose: To examine the relation between the lung elimination rate 
of inhaled technetium 99m (99mTc)-sestamibi and immu-
nohistochemical expression of bronchopulmonary multi-
drug resistance protein 1 (MRP1) and permeability glyco-
protein (P-gp) and assess the repeatability of the inhaled 
99mTc-sestamibi clearance technique.
Materials and 
Methods:
99mTc-sestamibi is a known substrate for P-gp and MRP1, 
which are established cellular drug efflux transporters. 
The elimination rate of 99mTc-sestamibi from the lungs af-
ter inhalation as an aerosol has been hypothesized to be 
regulated by expression of these transporters. Institutional 
ethics committee approval was received for this prospec-
tive study. Written informed consent was obtained from 
all participants. The clearance of inhaled 99mTc-sestamibi 
from the lungs of 13 patients due to undergo surgery for 
primary lung cancer (five of 13) or spontaneous pneumo-
thorax (eight of 13) was estimated after dynamic imaging 
of the lungs during a period of 40 minutes. The time taken 
to clear 50% of inhaled sestamibi (T1/2) was compared 
with a semiquantitative immunohistochemical assessment 
(grade 0–3) of MRP1 and P-gp expression in the lung by 
using parametric and nonparametric tests. The study was 
repeated in five participants to assess the repeatability of 
the technique by using a Bland Altman analysis method.
Results: MRP1 expression was seen in 12 of 13 patients, while 
P-gp expression was seen in only two. The mean 99mTc-
sestamibi elimination rate was faster in patients (n = 6) 
with low levels of MRP1 expression (grade 0–1) and mean 
T1/2 of 105 minutes 6 20 (standard deviation), compared 
with those with higher levels of MRP1 expression (grade 
2–3, n = 7) and mean T1/2 of 149 minutes 6 28 (P = 
.008). Bland-Altman analysis revealed excellent agreement 
between test and retest values.
Conclusion: Inhaled 99mTc-sestamibi clearance study is a repeatable 
technique demonstrating significant correlation with 
MRP1 expression in the lungs.
q RSNA, 2016
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The aims of the study were to ex-
amine the relation between the lung 
elimination rate of inhaled 99mTc-sesta-
mibi and immunohistochemical expres-
sion of bronchopulmonary MRP1 and 
P-gp and to assess the repeatability of 
the inhaled 99mTc-sestamibi clearance 
technique.
Materials and Methods
Institutional ethics committee approval 
was received for this prospective study. 
Written informed consent was ob-
tained from all participants. The study 
was conducted in compliance with the 
principles of the Declaration of Helsinki 
(1996), the principles of Good Clinical 
Practice, and all of the applicable regu-
latory requirements.
Patients attending the specialist 
adult thoracic surgical clinic for spon-
taneous pneumothorax and lung cancer 
management were screened to identify 
eligible participants. The inclusion cri-
teria included those aged 18 years or 
older and undergoing surgery for pri-
mary lung cancer or recurrent pneu-
mothorax. They were all able to pro-
vide informed consent and able to lie 
supine for 40 minutes under the gamma 
camera. The exclusion criteria included 
patients who were younger than 18 
years of age, pregnant, or if they were 
Multidrug resistance protein 1 
(MRP1), identified by Cole and Dee-
ley in 1992, has been the other most 
prominent protein that has been stud-
ied as a clinically relevant drug trans-
porter (14–19) and has been closely 
linked to the development of clinical 
multidrug resistance in several types of 
cancer (16). MRP1 is widely expressed 
in many human tissues and cancers 
(15), and its role in the transport of 
an extraordinarily wide variety of sub-
strates including a broad spectrum of 
anticancer drugs has been identified 
(14).
The radiopharmaceuticals techne-
tium 99m (99mTc)-sestamibi and 99mTc-
tetrofosmin, originally designed for 
myocardial perfusion studies, are well 
known substrates for both P-gp and 
MRP1 and have been described in the 
literature for the functional imaging of 
P-gp and MRP1 in humans (17–19). 
Many in vitro and in vivo studies have 
demonstrated correlation between the 
uptake and/or retention of these ra-
diopharmaceuticals and the expression 
levels of P-gp and/or MRP1 in tumor 
cells (17,20–22). Therefore, 99mTc-
sestamibi and 99mTc-tetrofosmin have 
been proposed as imaging probes for 
multidrug resistance assessment and 
to monitor the efficacy of multidrug re-
sistance modulators (23,24). All these 
studies have studied the handling of the 
radiopharmaceutical after intravenous 
injection but none have specifically 
looked at the cellular handling of in-
haled aerosols.
Recently, Ruparelia et al measured 
the clearance rate of 99mTc-sestamibi 
following inhalation as an aerosol from 
normal lungs in healthy nonsmoking hu-
mans (25). They observed that it was 
significantly slower than the clearance 
of the hydrophilic radioaerosol, 99mTc-
pentetate (25), and hypothesized that 
the delayed clearance of 99mTc-sestami-
bi was due to expression of P-gp in the 
airway epithelium (26). The clearance 
rate of inhaled 99mTc-sestamibi from the 
lungs was further significantly delayed 
in healthy smokers versus nonsmokers, 
and it was hypothesized that this was 
the result of smoke-induced up-regula-
tion of P-gp (25).
Published online before print
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Advances in Knowledge
 n The results of the study indicate 
strong expression of multidrug 
resistance protein 1 (MRP1) (12 
of 13) and weak (two of 13) or 
negative permeability glycopro-
tein expression in the human 
lungs.
 n There was a significant correla-
tion (P = .0001) between the 
clearance of inhaled technetium 
99m (99mTc)-sestamibi and MRP1 
expression in the lungs.
 n Inhaled 99mTc-sestamibi clearance 
analysis is a safe technique, with 
radiation exposure of less than 
0.5 mSv.
 n Inhaled 99mTc-sestamibi clearance 
is a repeatable technique, with a 
bias of 3.23% (4.7 minutes) and 
a precision of 3.9% (4.7 
minutes).
 n Inhaled 99mTc-sestamibi clearance 
technique demonstrates signifi-
cant interobserver correlation (R 
= 0.97265, two-tailed P , .001, 
and concordance correlation co-
efficient of 0.9865).
Chemotherapy for lung cancer was introduced in the late 1960s and has resulted in an increase in 
median survival and long-term disease-
free survival (1–3). Despite advances in 
cancer treatment, multidrug resistance 
to chemotherapy remains a major clin-
ical problem resulting in poor patient 
outcome due to limited therapeutic 
options. The mechanisms of resistance 
development are often diverse and in-
clude insufficient uptake of water-solu-
ble drugs by specific transporters, alter-
ations in cellular pathways, which result 
in a reduced capacity of cytotoxic drugs 
to kill cells, or increased drug efflux 
from cancer cells mediated by cellular 
drug transporters.
Permeability glycoprotein (P-gp), a 
170-kd ATP-dependent membrane trans-
porter that acts as a drug efflux pump 
(4,5), was originally described by Juliano 
and Ling in 1976, and its role as a drug 
transporter in various clinical settings 
has been studied extensively (6–13).
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study to assess the repeatability of the 
technique. A second experienced (6 
years) nuclear medicine physician re-
analyzed the inhaled 99mTc-sestamibi 
clearance in five patients to assess the 
correlation between the individual lung 
clearances and the mean clearance 
times.
Tissue Immunohistochemistry
Paraffin-embedded lung tissue obtained 
from the participants who underwent 
surgery for underlying disease was 
subjected to immunohistochemical 
examination for the presence of P-gp 
and MRP1. Immunohistochemistry was 
performed by using a staining machine 
(Ventana BenchMark ULTRA; Ventana 
Medical Systems, Tuscon, Ariz). Immu-
nostaining procedure was standardized 
by using control tissue. JSB-1 mouse 
antibody (ab3366; AbCam, Cambridge, 
United Kingdom) was used for P-gp de-
tection (1:50 dilution) and anti-MRP-1 
mouse antibody MRPm5 (ab24102; 
AbCam) was used for MRP1 detection 
(1:100 dilution).
The immunohistochemistry analysis 
was performed by an experienced (13 
years) lung histopathologist (P.C.). The 
healthy lung tissue around the patho-
logic cancerous tissue or bullous lung in 
patients with spontaneous pneumotho-
rax was clearly identified. The immu-
nohistochemical expression of P-gp and 
MRP1 in the healthy bronchoalveolar 
epithelial tissue was graded semiquan-
titatively (27) by the histopathologist 
based on the strength of immunostain-
ing and the number of cells staining for 
the protein per high-power field. The 
grading included four categories: neg-
ative = grade 0, weak = grade 1, mod-
erate = grade 2, and strong = grade 3.
The immunohistochemistry analyses 
(P.C.) and the inhaled 99mTc-sestamibi 
clearance analyses were performed in-
dependently by H.K.M. and a nonau-
thor, blinded to each other’s findings.
Statistical Analysis
Repeatability of the inhaled 99mTc-
sestamibi clearance technique was as-
sessed by using Bland-Altman analysis 
by testing agreement between the 
test and retest values. Mean inhaled 
by allowing for the differences in breath-
ing abilities between participants.
Participants were positioned supine 
on a camera couch (Symbia; Siemens, 
Erlangen, Germany). Anterior and pos-
terior images of the chest were acquired 
dynamically at a rate of 2 seconds per 
frame starting within a minute of com-
pleting the inhalation of the aerosol. 
Matrix size was 64 3 64 and no zoom 
was applied. The imaging continued up 
to 40 minutes. Images were transferred 
to Hermes (Hermes Medical, Stock-
holm, Sweden) workstation for analysis.
Analysis of Inhaled 99mTc-Sestamibi 
Clearance
Analysis of the dynamic images was 
performed by using Hermes worksta-
tion with the default dynamic study 
analysis software package. Regions of 
interest were drawn by an experienced 
(15 years) nuclear medicine physician 
(H.K.M.) around both lungs on the 
anterior and posterior images. Time-
activity curves were generated for both 
lungs from the geometric mean of the 
data. While analysis of the clearance 
was performed only on the posterior 
views of the lungs in the previous 
study (25), we used a geometric mean 
from anterior and posterior view as 
this would provide a more accurate 
measure of the clearance, partly ac-
counting for the depth-dependency of 
the activity distribution of the radio-
pharmaceutical and differential photon 
attenuation.
The effective half-time (T1/2) of the 
elimination of activity from the lungs 
was calculated by using an exponen-
tial fit to the data. An exponential fit 
to the data was applied, while in the 
previous study by Ruparelia et al (25) 
a linear fit was used. This was to avoid 
any assumptions, especially with the 
early part of the curve, which in the 
previous study (25) was not included. 
In this study, the imaging was com-
menced within a minute of completing 
inhalation, while in the previous study 
the imaging was commenced 6 minutes 
after completion of inhalation.
In five participants, the inhaled 
99mTc-sestamibi clearance study was re-
peated within 2–4 weeks of the initial 
receiving known P-gp/MRP1-modulat-
ing medication.
Nineteen potential patients were 
screened, of whom 13 (nine men) 
undergoing surgery for primary lung 
cancer (five of 13) or spontaneous 
pneumothorax (eight of 13) consented 
to the study. Of these, nine were ciga-
rette smokers. Mean age (6 standard 
deviation) for all the participants was 
48 years 6 24 (range, 19–78 years). 
Mean age of the male participants was 
50 years 6 25 (range, 19–78 years) 
and that for female patients was 45 
years 6 24 (range, 28–70 years). 
There was no statistically significant 
difference (t test, P = .36) in the mean 
ages between the male and female pa-
tients. All participants underwent in-
haled 99mTc-sestamibi clearance study 
prior to the proposed surgery, and 
immunohistochemical examination 
of the resected lung tissue for MRP1 
and P-gp expression was performed 
on the resected lung tissue. The in-
haled 99mTc-sestamibi clearance study 
was repeated in five consecutive par-
ticipants who consented to assess the 
repeatability of the technique. The re-
peat study was performed within 2–4 
weeks of the initial study and prior to 
the planned surgery. The participants 
did not undergo any intervention be-
tween the two studies. There was also 
no alteration in the participant’s phys-
ical condition between the two studies 
as assessed (H.K.M.) during interview 
prior to the imaging. The clearance 
rate of 99mTc-sestamibi from the lungs 
was correlated with a semiquantitative 
assessment (grade 0–3) of MRP1 and 
P-gp expression in lung tissue.
Inhaled 99mTc-Sestamibi Clearance Study 
Acquisition Parameters
A total of 400 MBq of 99mTc-sestamibi 
were placed in the SmartVent nebu-
lizer (Diagnostic Imaging, Welford, 
Northants, United Kingdom). The neb-
ulized radiopharmaceutical was inhaled 
for 1–5 minutes via a mouthpiece by the 
participant sitting upright until a mini-
mum count rate was observed over the 
lungs, at least 0.3 counts per second. 
The varied inhalation time was to ensure 
that minimum count rates were achieved 
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Repeatability of Inhaled 99mTc-Sestamibi 
Clearance Technique
Test-retest results in five participants 
who underwent repeat inhaled 99mTc-
sestamibi clearance study demonstrated 
good agreement between the two 
measurements. Bland-Altman analysis 
revealed a percentage mean difference 
between test and retest clearance half-
times (bias) of 3.23% and a percent-
age standard deviation of the difference 
(precision) of 3.9% (Fig 3).
A second experienced nuclear med-
icine reviewer analyzed the individual 
right and left lung clearances in five 
patients independent of reviewer 1. 
Spearman r analysis of the individual 
lung clearances between the first and 
second reviewer revealed a statistically 
significant relation (R = 0.97265, two-
tailed P , .001, and concordance cor-
relation coefficient of 0.9865).
Discussion
The expression of P-gp and MRP1 in 
the human lung (28) suggests that 
these transporters may play an im-
portant role in the protection against 
endogenous or exogenous toxic com-
pounds entering the lung. The delivery 
of inhaled drugs to reach their site 
of action may also be affected by the 
presence and activity of many cellular 
drug transporters (29). However, there 
those with low-grade expression, 0 and 
1, and those with higher grade expres-
sion, 2 and 3, as in previous study (27).
Analysis of Inhaled 99mTc-Sestamibi 
Clearance
The clearance of inhaled 99mTc–sestami-
bi for individual lungs was obtained and 
compared. A Spearman r and concor-
dance correlation coefficient test con-
firmed an excellent correlation between 
the right and left lung clearances in the 
first study and the repeat study (P , 
.00, R = 0.9634, and correlation coeffi-
cient = 0.9901).
Analysis of clearance of inhaled 
99mTc-sestamibi from the lungs of the 
participants was significantly delayed in 
seven patients demonstrating upregu-
lated MRP1 (grade 2–3, T1/2 = 149 
min 6 28) compared with six patients 
expressing low MRP1 levels (grade 0–1, 
T1/2 = 105 min 6 20), Student t test P 
= .008 and Mann Whitney U test P , 
.05 (Fig 2a, 2b).
A further Spearman rank order 
test confirmed a significant correlation 
between the four different grades of 
immunohistochemical staining versus 
clearance of inhaled 99mTc-sestamibi 
from the lungs (P = .0001). The mean 
clearance of inhaled sestamibi from 
individual patients and the respective 
MRP1 expression grading are present-
ed in the Table.
99mTc-sestamibi clearance values and 
standard deviation were calculated. 
Parametric testing using Student t 
test and a nonparametric testing using 
Mann-Whitney test and a Spearman 
rank correlation test were applied to 
the data comparing the clearance half-
time to the immunohistochemistry 
grading. Spearman r and concordance 
correlation coefficient test were used 
to test the correlation between the in-
dividual lung clearances and the mean 
clearance times assessed by the two 
reviewers.
Results
Tissue Immunohistochemistry
At immunohistochemical analysis of 
the lung tissue in 13 participants, the 
expression of P-gp within the nor-
mal bronchoalveolar epithelial tis-
sue was negative (grade 0) (Fig 1a) 
in 11 patients and only weakly pos-
itive (grade 1) in two patients. MRP1 
expression was demonstrated within 
the normal bronchoalveolar epithe-
lium in 12 of 13 patients (Fig 1b) 
and was negative in only one patient. 
Five patients demonstrated grade 1 
MRP1 expression, while six patients 
demonstrated grade 2 and one patient 
demonstrated grade 3 expression. The 
patients were divided into two groups: 
Figure 1
Figure 1: Photomicrographs (immunohistochemistry of P-gp and MRP1) of immunostaining of healthy bronchoalveolar 
epithelium in a patient demonstrate (a) negative P-gp staining with very little or no brown staining (arrows point to blue negative 
staining lining cells of the bronchoalveolar epithelium) and (b) intense brown staining for MRP1 expression (arrows point to 
brown positive staining lining cells of the bronchoalveolar epithelium).
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alveolocapillary membrane by using an 
inhaled clearance technique provides 
a model to directly interrogate the ef-
fects of drug transporters on a large 
variety of inhaled pulmonary thera-
peutic agents, such as corticosteroids 
and sympathomimetics that may be 
substrates for these transporters in the 
lung or modulate their activity. Func-
tional inhalation studies would also pro-
vide an opportunity to demonstrate the 
effects of inhaled toxic substances, as 
postulated by van der Deen et al (31).
Inhaled 99mTc-sestamibi clearance 
is a functional imaging technique that 
was first described by Ruparelia et al in 
2008 (25). They studied the clearance 
of inhaled 99mTc-sestamibi in healthy 
human volunteers and patients with 
chronic obstructive pulmonary disease 
(COPD). They observed significant dif-
ferences (. 20%) in inhaled 99mTc-ses-
tamibi clearance rates between smokers 
and nonsmokers, while no significant 
difference was seen between healthy 
volunteers compared with COPD pa-
tients. They postulated that the delayed 
clearance of 99mTc-sestamibi across the 
alveolocapillary barrier was regulated 
by active binding and efflux of 99mTc-
sestamibi by P-gp expressed in the lung 
tissue (26). They also postulated that 
delayed 99mTc-sestamibi clearance in 
smokers compared with nonsmokers 
and protection against air pollution 
and inhaled toxic substances, such as 
those present in cigarette smoke (31). 
Indeed, Van der deen et al observed 
lower MRP1 expression in patients 
with chronic airway disease and pos-
tulated that the lower expression of 
MRP1 or the down-regulation of MRP1 
may result in an increased vulnerabil-
ity to, and subsequent development of, 
chronic airway disease (31).
Imaging the kinetics of known 
drug transporter substrates across the 
remains a debate about the role of P-gp 
as a major drug transporter in human 
lungs. The current opinion is that P-gp 
is mainly expressed in the larger tra-
cheobronchial airway epithelium, while 
there is no significant expression in 
bronchoalveolar epithelium (30).
Given the fact that MRP1 expres-
sion is higher in the lung compared 
with other solid organs, decreased or 
increased functional MRP1 expression 
may have a high impact on development 
and/or progression of lung diseases 
Figure 2
Figure 2: Inhaled 99mTc-sestamibi clearance in (a) a patient with low MRP1 expression and demonstrat-
ing a faster clearance time and in (b) a patient with high MRP1 expression and demonstrating prolonged 
clearance time.
Individual Mean Inhaled Sestamibi 
Clearance Compared with the 
Histologic Grading
Mean Clearance (min) MRP1 Expression Grade
75.5 0
123 1
110.5 1
83.5 1
119 1
117.5 1
134.5 2
110 2
175.5 2
163 2
123 2
149.5 2
185.5 3
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imaging studies demonstrating the role 
of MRP1 in lungs.
This study has limitations. The 
number of patients was small, which 
makes interpretation of the results, 
although significant, at best a relation 
rather than causal effect. We also did 
not look at possible regional variation 
of the clearance values and did not an-
alyze the clearance specifically related 
to tumor tissue compared with the 
normal lung tissue. However, given the 
size of the pathologic finding, which 
was 1–4 cm maximum in all cases, it 
was considered too small to attempt to 
correlate spatially with regions of in-
terest on the dynamic images, which 
are subject to patient motion and re-
spiratory motion, which would affect 
the spatial correlation. In addition, 
due to the influence of noise in the dy-
namic images, the use of small regions 
of interest would also lead to errors 
related to this analysis.
Nonetheless, this study is the first 
in vivo study, to our knowledge, that 
demonstrates a correlation between 
lung MRP1 expression and inhaled 
99mTc-sestamibi clearance, which is a 
safe (radiation exposure , 0.5 mSv) 
and a repeatable technique. The results 
of this study do raise the need for a 
further prospective study with larger 
numbers to assess if these results could 
be replicated. Further studies should 
also look at the effect of specific MRP1 
blockers to address the causal relation 
and assess the effect of other covari-
ables, including smoking status, effect 
of age and sex on the clearance of in-
haled 99mTc-sestamibi.
In conclusion, inhaled 99mTc-sestami-
bi clearance presents a safe and repeat-
able technique demonstrating a correla-
tion between bronchoalveolar expression 
of MRP1 and clearance of inhaled 99mTc-
sestamibi. There was no substantial P-gp 
expression identified in the normal lung 
tissue. Further research is needed to as-
sess the factors influencing the clearance 
of inhaled 99mTc-sestamibi and determine 
the potential applicability of these find-
ings in clinical practice.
Disclosures of Conflicts of Interest: H.K.M. 
disclosed no relevant relationships. T.R. dis-
closed no relevant relationships. P.C. disclosed 
Ruparelia et al (25), who also observed 
prolonged inhaled 99mTc-sestamibi 
clearance in smokers compared with 
nonsmokers, although they did not have 
immunohistochemical confirmation.
While immunohistochemistry is re-
garded as the reference standard for de-
termination of MRP1 expression in lung 
epithelium, the technique is limited by 
heterogeneous expression of drug trans-
porters in the lung tissue. The demon-
stration of expression is dependent on 
antibody selection and also remains 
tissue-dependent (13). Immunoreac-
tivity is not specific, which could result 
in false-positive results. Other potential 
problems include sampling errors, tissue 
fixation effects (8), and failure of protein 
expression to translate to function. In 
contrast, functional imaging using ra-
diolabeled drug transporter substrates 
represents an attractive alternative for 
the in vivo measurement of functional 
expression and moreover is independent 
of histologic sampling errors.
However, on review of the litera-
ture, functional imaging studies dem-
onstrating the role of MRP1 in lungs 
remains very limited. Apart from a 
single animal study by Okamura et al 
(32), who demonstrated MRP1 as the 
prime drug transporter across the lung 
epithelium with P-gp playing no signif-
icant role, there is a lack of functional 
was due to the active efflux of inhaled 
99mTc-sestamibi mediated by increased 
P-gp expression in the alveolar epi-
thelium, pumping it back into the air-
spaces (25). Interestingly, this group 
showed no difference between smokers 
and nonsmokers with respect to the 
lung clearance rate of inhaled 99mTc-
tetrofosmin (26). There was, however, 
no immunohistochemical correlation 
available to confirm the postulation.
In the present study, very little 
or no P-gp expression was identified, 
while in contrast, there was clear 
MRP1 expression noted at immuno-
histochemical analysis of thee healthy 
lung tissue. Furthermore, we demon-
strate a significant delay in the clear-
ance of inhaled 99mTc-sestamibi, an 
established MRP1 substrate, from the 
lungs in patients with higher MRP1 
expression (grade 2 or 3, n = 7) com-
pared with those with low or no MRP1 
expression (grade 0 or 1, n = 6).
Interestingly, we observed that all 
seven patients expressing higher MRP1 
levels were also smokers and correspond-
ingly demonstrated prolonged inhaled 
99mTc-sestamibi clearance time. While 
the up-regulation of MRP1 in metaplastic 
lung epithelium following exposure to cig-
arette smoke has been observed by van 
der Deen et al (31), the current study 
results are similar to the observations of 
Figure 3
Figure 3: Bland-Altman analysis demonstrates excellent agreement between 
test and retest inhaled 99mTc-sestamibi (MIBI) clearance rates. ST DEV = 
standard deviation.
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no relevant relationships. L.L. disclosed no 
relevant relationships. J.R.B. disclosed no rele-
vant relationships. A.M.P. disclosed no relevant 
relationships.
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